GREEN CROSS

Search
Keyword Search
Plasma Derivatives Office Vaccines Subsidiary Pipeline R&D Media Stock Company Recruit
Product Search
close
Total Menu KOR
close

R&DR&D Story

Green Cross specializes in the development of essential but difficult-to-make drugs

lab

Hemophilia

Prior to 1990, the average lifespan for a person with hemophilia in S.Korea was only 18 years, compared to 60 years for a person with hemophilia in Germany. Taking upon itself the mission to extend both quality of life and life expectancy for Koreans suffering from this disorder, Green Cross found success in Facnyne (plasma-derived factor IX) and Green VIII (plasma-derived factor VIII). It went on to develop Green Gene, a recombinant protein, and then Green Gene-F, which was made safer by removing albumin. Thanks to these innovative endeavors, the average lifespan of patients with hemophilia has increased to 74 years today. Refusing to rest on its laurels, Green Cross continues to develop long-acting and new-antibody cures for hemophilia.

center

Plasma Derivatives

Green Cross, a world-renowned expert on plasma-derived products, continues to enhance its already government-approved products by improving quality and diversifying available doses and types. The company is rapidly expanding abroad, starting with the launch of its immunoglobulin (IVIG-SN)in the U.S. market.

After the dawn of the new millennium, Green Cross began to expand its exclusive vaccine manufacturing facilities and accelerate its related R&D. The company played a major role in protecting the nation against the H1N1 flu virus, a pandemic that swept across the world in 2009, through development and release of its GC Flu (a seasonal trivalent flu vaccine, government-approved in 2009) and Green Flu-S (2009), as well as Green Flu-S Plus (2010), which contained immunity enhancers. Green Cross’ research success garnered recognition for the company as an exemplary model at the World Health Organization (WHO) meetings. Accordingly, our flu vaccines became the first in Asia and the fourth in the world to win WHO prequalification, a necessary step to participate in international bidding. In 2015, GC Flu became the first in Korea and the second in the world to win prequalification for a quadrivalent flu vaccine (GC Flu Quadrivalent), raising expectations for an expanding presence on the global market.

In 2016, Green Cross also became the first Korean developer and manufacturer of a Td vaccine, protecting the population against diphtheria and tetanus. The company intends to research and develop a new vaccine (Tdap or DTaP) to immunize against tetanus, diphtheria, and pertussis together.

Green Cross has access to a variety of vaccine pipelines, and continues to further develop its already government-approved vaccines to meet global standards.

Vaccines

world map

lab images

Vaccines form another key interest area for Green Cross . Green Cross became the third company in the world to develop its own formula for preventing hepatitis-B, named Hepavax-B(government-approved in 1983). The company went on to become the first in the world to develop a vaccine against hemorrhagic fever with renal syndrome, named Hantavax (government-approved in 1990), and the second in the world to develop a varicella zoster vaccine, named Suduvax (government-approved in 1993). These achievements served to strengthen its reputation as a pioneer in vaccines.

Rare Diseases

New drug pipelines are also opening up, including for orphan drugs for rare diseases.

Through prompt alignment of its related systems and commercial capabilities, Green Cross was able to expedite R&D for Hunterase (2012), which is the second treatment in the world to be developed for Hunter syndrome. The drug has replaced the need for expensive imported drugs, thereby significantly improving access to effective treatment for persons suffering from this rare disease.

camical

Oncology, Immunology
& Cell-therapy

Green Cross also found success in Neulapeg, a treatment for neutropenia, in 2014. Supplementing the anti-carcinogenic regimen designed to help patients with depressed immune systems from chemotherapy, Neulapeg offers a longer half life than first–generation treatments, thereby improving patient convenience and also enabling replacement of treatments imported to Korea.

Based on its extensive expertise in immunology and mammalian cell platform technology, Green Cross continues to introduce innovative antibody manufacturing techniques and develop new candidates for cancer immunotherapy. Through its specialized subsidiaries, Green Cross continues to strengthen its position in cell therapy, which is now emerging as a new source for future economic growth.

Future Strategy

With its expertise in plasma-derived products, vaccines, and recombinant protein treatments,
the company will maximize the value of its existing products, harness its disease-fighting R&D
pipelines, and continue to use strategic R&D innovation to develop new drugs.

Related Link